ClinicalTrials.gg

Program

nelistotug

Also written as “Nelistotug” and “GSK6097608”.

Its studies are mostly in Neoplasms · Carcinoma, Non-Small-Cell Lung · Squamous Cell Carcinoma of Head and Neck, led by GlaxoSmithKline.

Furthest: phase 2, since Nov 9, 20186 company-led studies, 4 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline64 open or runningphase 2since Nov 9, 2018Nov 9, 2018Dec 31, 2026phase 1 · NCT04446351

Also a collaborator on its studies: iteos-therapeutics, 23andme-inc and iteos-belgium-sa.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 9, 2018First study: phase 2 study in NeoplasmsFirst studyNCT03739710 · 175 enrolled · United States, Canada, France and more
  2. Jun 22, 2020Phase 1 study in NeoplasmsNCT04446351 · 107 enrolled · United States, Canada, Japan and more
  3. Mar 3, 2022Phase 1 study in NeoplasmsNCT05277051 · 152 enrolled · United States, Australia, Canada and more
  4. Sep 30, 2022Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05565378 · 351 enrolled · United States, Argentina, Belgium and more
  5. Sep 21, 2023Phase 2 study in Head and Neck NeoplasmsNCT06062420 · 316 enrolled · United States, Argentina, Brazil and more
  6. Apr 11, 2025Phase 2 study in NeoplasmsNCT06926673 · 62 enrolled · United States, Canada, France and more

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in NeoplasmsNCT04446351

TargetBeta

CD96 →read by rule
“A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor CD96 (Tactile; T cell activation increased late expression), ”NCIt, by rule

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06926673Neoplasms · United States, Canada, France and more2CompletedMay 2, 202462
NCT06062420Head and Neck Neoplasms · United States, Argentina, Brazil and more2Active, not recruitingSep 10, 2026316
NCT05565378Carcinoma, Non-Small-Cell Lung · United States, Argentina, Belgium and more2Active, not recruitingOct 26, 2026351
NCT05277051Neoplasms · United States, Australia, Canada and more1Active, not recruitingJun 30, 2026152
NCT04446351Neoplasms · United States, Canada, Japan and more1Active, not recruitingDec 31, 2026107
NCT03739710Neoplasms · United States, Canada, France and more2CompletedMay 2, 2024175

How it is read

Names in the registry

  • “Nelistotug”, 4 entries
  • “GSK6097608”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.